Deregistration notice
Open the filing on sec.gov
Supernus Pharmaceuticals, Inc. (SUPN)
SUPN · Pharmaceutical Preparations · Rockville, MD · filing with the SEC since 2006
Grade5.9
◀ Past 5.2● Present 7.1▶ Future 5.0
The companyfiscal 2025, as filed
Revenue$719M+8.6%
Net income-$38.5M-152.2%
Earnings per share$-0.68-151.5%
Operating cash flow$47.3M-72.5%
Cash$128M+85.3%
Debtn/a
Shareholders’ equity$1.06B+2.5%
Shares, diluted56.5M+0.9%
Return on equity-3.6%
The recordfrom its filings
Filings in 2026129
Newest filingNov 12 · 15-12G
Annual reportMar 2, 2026
Quarterly reportOct 29, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$10.3M
Insider buys, 12 months$0.00
Patents granted206
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $865MNet income -$43.9MCash from operations $88.2Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.